Elizabeth W. Lampe - 0824 The Effect of CBT-I Dose on Sleep Outcomes

Journal article

A. Muench, E. Lampe, D. Posner, Mark Seewald, J. Boyle, Ivan Vargas, M. Thompson, M. Grandner, M. Perlis
Sleep, 2023

Cite

APA Click to copy
Muench, A., Lampe, E., Posner, D., Seewald, M., Boyle, J., Vargas, I., … Perlis, M. (2023). 0824 The Effect of CBT-I Dose on Sleep Outcomes in Cancer Survivors at 3-month Follow-up. Sleep.

Chicago/Turabian Click to copy
Muench, A., E. Lampe, D. Posner, Mark Seewald, J. Boyle, Ivan Vargas, M. Thompson, M. Grandner, and M. Perlis. “0824 The Effect of CBT-I Dose on Sleep Outcomes in Cancer Survivors at 3-Month Follow-Up.” Sleep (2023).

MLA Click to copy
Muench, A., et al. “0824 The Effect of CBT-I Dose on Sleep Outcomes in Cancer Survivors at 3-Month Follow-Up.” Sleep, 2023.

BibTeX Click to copy

@article{a2023a,
  title = {0824 The Effect of CBT-I Dose on Sleep Outcomes in Cancer Survivors at 3-month Follow-up},
  year = {2023},
  journal = {Sleep},
  author = {Muench, A. and Lampe, E. and Posner, D. and Seewald, Mark and Boyle, J. and Vargas, Ivan and Thompson, M. and Grandner, M. and Perlis, M.}
}

Abstract

Cancer-related fatigue (CRF) is highly prevalent during acute illness and survivorship, with almost 100% of cancer patients experiencing such symptomatology. While CRF commonly co-occurs with sleep disturbance during and/or after cancer treatment, CRF is (nevertheless) defined as occurring independent of sleep considerations. Last year it was reported (based on preliminary findings from a pilot study), that CBT-I affects both sleep continuity and fatigue, with high dose CBT-I producing up to a 72% reduction in pre-to-post measures of Fatigue. The present analysis is based on a completed pilot study where we evaluate the durability of the anti-fatigue and sleep continuity effects of CBT-I in patients diagnosed with breast and prostate cancer.

This descriptive analysis (percent change from post-treatment to three month follow-up) includes 11 adult subjects (91% female; Mage=57.8±7.7yrs). CBT-I was provided by a master CBT-I therapist via video conferencing (telehealth CBT-I). Subjects were asked to complete sleep diaries, and weekly measures of fatigue (FACIT), and insomnia severity (ISI) questionnaires. In order to evaluate durability, post-treatment scores were compared to three-month follow-up scores, where all subjects were typed for whether or not they retained > 90% of their clinical gains as assessed with the ISI and the FACIT.

82% of the subjects in our pilot study maintained their clinical gains with respect to fatigue and 64% maintained their gains with respect to insomnia.

This preliminary analyses suggest that clinical gains via CBT-I are remarkably robust for fatigue outcomes. The findings with respect to the ISI, while less robust, are within the range that is typical for insomnia RCTs (~70% of subjects maintain treatment responses at follow-ups). If these results are replicated, this may suggest that the anti-fatigue effects of CBT-I are more durable than the “insomnialytic” effects.

5T32HL00795320;K24AG055602